Auspex adds weight as it raises $25m to progress deuterium-modified pipeline
This article was originally published in Scrip
Auspex Pharmaceuticals has raised $25 million in a Series D venture financing round to conduct a pivotal Phase III clinical trial for SD-809, a version of the drug Xenazine (tetrabenazine) for the treatment of chorea associated with Huntington's disease, in which the San Diego-based company believes it has improved pharmacokinetic properties by substituting certain hydrogen atoms with the "heavy" hydrogen isotope deuterium.
You may also be interested in...
Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going public this month. Also, Moderna floats a $500m offering, Revance proposes a $20m note sale, and Nestle invests another $200m in Aimmune.
Biohaven is still studying its glutamate modulator in three other indications, but its biggest near-term milestone will be approval of the oral CGRP inhibitor rimegepant for acute migraine.
Despite positive Phase III results in Lennox-Gastaut syndrome, the effect of the company’s low-dose fenfluramine on serious seizures may not be as good as seen with GW Pharma’s Epidiolex.